Nanoparticle anchoring targets immune agonists to tumors enabling anti-cancer immunity without systemic toxicity
Immunostimulatory agents used in cancer treatment often elicit serious toxicities, limiting their clinical application. Here, the authors show that the use of liposomes to intravenously deliver surface-anchored IL-2 and anti-CD137 proteins enables anti-cancer immunity and reduces the toxic side effe...
Guardado en:
Autores principales: | Yuan Zhang, Na Li, Heikyung Suh, Darrell J. Irvine |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/3d4040a0e60d452b9cad0c19ca4f203c |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity
por: Marta Compte, et al.
Publicado: (2018) -
T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity
por: Daniela Schmid, et al.
Publicado: (2017) -
Melittin-lipid nanoparticles target to lymph nodes and elicit a systemic anti-tumor immune response
por: Xiang Yu, et al.
Publicado: (2020) -
Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity
por: Daniel S. Leventhal, et al.
Publicado: (2020) -
Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer
por: Dobrin Draganov, et al.
Publicado: (2021)